Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist
Chris M. Storgard, … , Robert I. Fox, David A. Cheresh
Chris M. Storgard, … , Robert I. Fox, David A. Cheresh
Published January 1, 1999
Citation Information: J Clin Invest. 1999;103(1):47-54. https://doi.org/10.1172/JCI3756.
View: Text | PDF
Article

Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist

  • Text
  • PDF
Abstract

Rheumatoid arthritis (RA) is an inflammatory disease associated with intense angiogenesis and vascular expression of integrin αvβ3. Intra-articular administration of a cyclic peptide antagonist of integrin αvβ3 to rabbits with antigen-induced arthritis early in disease resulted in inhibition of synovial angiogenesis and reduced synovial cell infiltrate, pannus formation, and cartilage erosions. These effects were not associated with lymphopenia or impairment of leukocyte function. Furthermore, when administered in chronic, preexisting disease, the αvβ3 antagonist effectively diminished arthritis severity and was associated with a quantitative increase in apoptosis of the angiogenic blood vessels. Therefore, angiogenesis appears to be a central factor in the initiation and persistence of arthritic disease, and antagonists of integrin αvβ3 may represent a novel therapeutic strategy for RA.

Authors

Chris M. Storgard, Dwayne G. Stupack, Alfred Jonczyk, Simon L. Goodman, Robert I. Fox, David A. Cheresh

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Blockade of integrin αvβ3 decreases pannus formation and cartilage erosi...
Blockade of integrin αvβ3 decreases pannus formation and cartilage erosions. (a) Pannus development (arrowheads) was graded on a relative scale 0–5 (0 = normal to 5 = macroscopic erosion). Treatment with the αvβ3 antagonist significantly decreased pannus formation (P < 0.05, Student's t test) relative to control peptide. (b) Frontal sections of decalcified femoral condyle stained by H&E illustrate the protective effect of αvβ3 antagonist treatment on a representative sample of erosive disease (×10). (P indicates pannus, E indicates erosion, and the arrowhead indicates preservation of the articular cartilage in the antagonist-treated group.) Macroscopic cartilage erosions were decreased with αvβ3 antagonist treatment (P < 0.01, Student's t test). All data are expressed as mean ± SE (n = 20).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts